Document is current
Any future updates will be listed below
-
Authors
Pai, Victor J.
Lau, Calvin J.
Garcia-Ruiz, Almudena
Donaldson, Cynthia
Vaughan, Joan M.
Miller, Brendan
De Souza, Eduardo V.
Pinto, Antonio M.
Diedrich, Jolene
Gavva, Narender R.
Yu, Shan
DeBoever, Christopher
Horman, Shane R.
Saghatelian, Alan
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (F32-DK132927)
National Institute of General Medical Sciences (R01-GM102491)
National Institute of General Medical Sciences (R01-GM102491)
National Institute of General Medical Sciences (R01-GM102491)
National Institute of General Medical Sciences (R01-GM102491)
National Cancer Institute (P30-CA014195)
National Cancer Institute (P30-CA014195)
National Cancer Institute (P30-CA014195)
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 24 October 2024
First Online: 5 November 2024
Declarations
:
: Not applicable. Ethics approval and consent to participate was not required as the study did not involve human or animal subjects.
: Not applicable. This study used downloaded public data and thus no consent to publish was necessary.
: The authors declare the following competing interests. Alan Saghatelian is a consultant for and cofounder of Exo and Velia Therapeutics. The authors who were affiliated with Takeda Development Center Americas were employees of Takeda Pharmaceuticals during the course of this work, and have real or potential ownership interest in Takeda. All the other authors do not have any competing interest.
